Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation
DUBLIN, July 9, 2014 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/3pfrzt/frontier_pharma) has announced the addition of the "Frontier Pharma: Psoriasis - Identifying and Commercializing First-in-Class Innovation" report to their offering.
http://photos.prnewswire.com/prnh/20130307/600769
Over the last decade, a greater understanding of the underlying pathophysiology of psoriasis has increased emphasis on developing immuneomodulating therapies, as opposed to largely symptomatic treatments. This is currently reflected in a competitive market dominated by multiple disease-modifying biologic therapies (inhibitors of TNF-a and IL-12/IL-23) and generic small-molecule therapies. Despite this, there are significant unmet needs in the market, including safety concerns regarding immunomodulation. This is a particularly important issue for the long-term commercial and clinical success of psoriatic therapeutics, especially for emerging biologics. Another unmet need is ease of drug application, as biologic drug delivery is invasive and painful.
Scope:
- A brief introduction to psoriasis, including symptoms, pathophysiology, and overview of pharmacotherapy
- The changing molecular target landscape between market and pipeline and particular focal points of innovation
- Overview of how innovative products are contributing to the pipeline and market for psoriasis
- Comprehensive review of the pipeline for first-in-class therapies, analyzed on the basis of phase distribution, molecule type, molecular target, and administration route
- Identification and assessment of first-in-class molecular targets with a particular focus on early-stage programs of which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets
- Assessment of the licensing and co-development deals for psoriasis therapies
Key Topics Covered:
1 Table of Contents
2 The Case for Innovation
3 Clinical and Commercial Landscape
4 Assessment of Psoriasis Pipeline and Innovation
5 First-in-Class Target and Pipeline Program Evaluation
6 Deals and Strategic Consolidations
7 Appendix
For more information visit http://www.researchandmarkets.com/research/3pfrzt/frontier_pharma
Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net
Share this article